Kala Pharmaceuticals Inc (KALA) Shares Bought by Wells Fargo & Company MN

Share on StockTwits

Wells Fargo & Company MN boosted its position in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) by 26.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,289 shares of the company’s stock after acquiring an additional 76,595 shares during the period. Wells Fargo & Company MN owned 1.48% of Kala Pharmaceuticals worth $5,751,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Teachers Advisors LLC increased its holdings in shares of Kala Pharmaceuticals by 44.6% during the 4th quarter. Teachers Advisors LLC now owns 21,006 shares of the company’s stock worth $388,000 after purchasing an additional 6,478 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of Kala Pharmaceuticals by 48.4% during the 4th quarter. TIAA CREF Investment Management LLC now owns 28,340 shares of the company’s stock worth $524,000 after purchasing an additional 9,247 shares during the period. Deutsche Bank AG increased its holdings in shares of Kala Pharmaceuticals by 126.1% during the 4th quarter. Deutsche Bank AG now owns 19,096 shares of the company’s stock worth $352,000 after purchasing an additional 10,651 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Kala Pharmaceuticals during the 4th quarter worth about $235,000. Finally, Millennium Management LLC increased its holdings in shares of Kala Pharmaceuticals by 67.4% during the 4th quarter. Millennium Management LLC now owns 103,400 shares of the company’s stock worth $1,912,000 after purchasing an additional 41,637 shares during the period. 76.84% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on KALA. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Kala Pharmaceuticals in a report on Wednesday, June 20th. ValuEngine upgraded shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. BidaskClub downgraded shares of Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. Finally, Zacks Investment Research upgraded shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $36.00.

Kala Pharmaceuticals opened at $13.85 on Friday, MarketBeat reports. Kala Pharmaceuticals Inc has a 52-week low of $11.81 and a 52-week high of $26.75. The company has a current ratio of 20.40, a quick ratio of 20.40 and a debt-to-equity ratio of 0.25. The stock has a market cap of $332.08 million and a PE ratio of -2.37.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). research analysts expect that Kala Pharmaceuticals Inc will post -1.97 earnings per share for the current year.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Want to see what other hedge funds are holding KALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kala Pharmaceuticals Inc (NASDAQ:KALA).

Institutional Ownership by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply